Skip to main content
Wolverine Dr

A regenerative-research digest on the Wolverine blend — BPC-157 and TB-500 read across the published tissue-repair literature, with the regulatory and compounded-access record set down plainly.

The numbered notes lead to the original papers

BPC-157 TB-500 is a proposed healing mixture with separate research papers.

The list below contains ingredient studies and FDA pharmacy notices. You can look up the printed number beside an injury claim to find its paper. Look at the ingredient given and the people or animals treated.

Read the results in plain wordsLook at what newer reviewers found

Each study number identifies the paper behind a claim

Giving BPC-157 TB-500 together has no proved healing benefit. You can find the papers behind the separate ingredient claims below. Entries 1–5 cover earlier tendon experiments and blood-vessel growth. They also cover cell movement, whole Thymosin Beta-4, and identifying TB-500. Entries 6–12 contain animal experiments and reviews from 2024–2026. Entries 13–15 explain FDA's 503A pharmacy rules, Category 2 safety warnings, withdrawn requests, and the July 2026 meeting.

Find the printed claim number among the entries below to check whether scientists treated people, animals, or cells, and whether the finding actually concerned the mixture or one ingredient.

The BPC-157 TB-500 study amounts page explains what scientists gave. Those figures describe experiments, not a safe amount for your care.

  1. Staresinic M, et al. Gastric pentadecapeptide BPC 157 accelerates healing of transected rat Achilles tendon and in vitro stimulates tendocytes growth. J Orthop Res. 2003;21(6):976-983. ↗
  2. Hsieh MJ, et al. Therapeutic potential of pro-angiogenic BPC157 is associated with VEGFR2 activation and up-regulation. J Mol Med (Berl). 2017;95:323-333. ↗
  3. Irobi E, et al. Structural basis of actin sequestration by thymosin-beta4: implications for WH2 proteins. EMBO J. 2004. ↗
  4. Goldstein AL, Hannappel E, Sosne G, Kleinman HK. Thymosin beta4: a multi-functional regenerative peptide. Basic properties and clinical applications. Expert Opin Biol Ther. 2012. ↗
  5. Esposito S, et al. Synthesis and characterization of the N-terminal acetylated 17-23 fragment of thymosin beta 4 identified in TB-500, a product suspected to possess doping potential. Drug Test Anal. 2012. ↗
  6. Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review. HSS J. 2025. ↗
  7. Mendias CL, Awan TM. Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance. Sports Med. 2026. ↗
  8. Regeneration or Risk? A Narrative Review of BPC-157 for Musculoskeletal Healing. Curr Rev Musculoskelet Med. 2025. ↗
  9. Stable Gastric Pentadecapeptide BPC 157 as Therapy After Surgical Detachment of the Quadriceps Muscle from Its Attachments for Muscle-to-Bone Reattachment in Rats. Pharmaceutics. 2025. ↗
  10. Protective Effects of BPC 157 on Liver, Kidney, and Lung Distant Organ Damage in Rats with Experimental Lower-Extremity Ischemia-Reperfusion Injury. Medicina (Kaunas). 2025. ↗
  11. Multifunctionality and Possible Medical Application of the BPC 157 Peptide - Literature and Patent Review. Pharmaceuticals (Basel). 2025. ↗
  12. The Stable Gastric Pentadecapeptide BPC 157 Pleiotropic Beneficial Activity and Its Possible Relations with Neurotransmitter Activity. Pharmaceuticals (Basel). 2024. ↗
  13. U.S. Food and Drug Administration. Certain Bulk Drug Substances for Use in Compounding That May Present Significant Safety Risks (BPC-157 and 'Thymosin beta-4, fragment (LKKTETQ), also known as TB-500' entries; Category 2, effective with the September 29, 2023 update). ↗
  14. U.S. Food and Drug Administration. Bulk Drug Substances Used in Compounding Under Section 503A of the FD&C Act (Category 1 and Category 2 definitions; 503A/503B framework and bulks-list nomination process). ↗
  15. U.S. Food and Drug Administration. July 23-24, 2026: Meeting of the Pharmacy Compounding Advisory Committee (BPC-157 and TB-500 listed as substances 'being considered for inclusion on the 503A Bulks List'; placed on the agenda, not decided). ↗
  16. Cha HJ, Jeong MJ, Kleinman HK. Role of thymosin beta4 in tumor metastasis and angiogenesis. J Natl Cancer Inst. 2003. ↗
  17. Ho ENM, et al. Doping control analysis of TB-500, a synthetic version of an active region of thymosin beta4, in equine urine and plasma by liquid chromatography-mass spectrometry. J Chromatogr A. 2012. ↗
  18. Ruff D, et al. A randomized, placebo-controlled, single and multiple dose study of intravenous thymosin beta4 in healthy volunteers. Ann N Y Acad Sci. 2010. ↗
  19. et al. A first-in-human, randomized, double-blind, single- and multiple-dose, phase I study of recombinant human thymosin beta4 in healthy Chinese volunteers. J Cell Mol Med. 2021. ↗